Last year, Spanish dermatology firm Almirall entered a license and commercialization agreement with Danish MC2 Therapeutics, gaining the European rights for the latter company’s plaque psoriasis cream, Wynzora.
Almirall has now initiated the launch of the cream in Europe, the company announces in a press release.
The rollout will begin on the Spanish, German and UK markets, with more European markets expected to follow in coming months.
”The launch of Wynzora cream in Europe represents a step forward in our commitment to offering innovative therapies that improve the quality of life of patients with psoriasis,” says CEO at Almirall Gianfranco Nazzi in the statement, adding:
”Currently, 73 percent of patients are not adhering to topical treatments. In view of this worrying lack of adherence to such treatments, Almirall is convinced that this new product, with proven efficacy and a patient-friendly formulation, will mark a turning point by improving psoriasis patients’ satisfaction thanks to its less greasy formulation.”
MC2 Therapeutics launched Wynzora on the US market last year, in a collaboration with Epi Health.
Express Scripts to cover psoriasis cream from MC2 Therapeutics
MC2 Therapeutics launches psoriasis cream in US
Almirall partner MC2 on the verge of EU victory after ten years of hard work
More from MedWatch
Ambu board had started headhunting process long before firing of CEO
Thursday’s CEO change had been in the works for a while, says Ambu’s board chair Jørgen Jensen.
Nine new drugs recommended for approval by CHMP at May meeting
During this month’s meeting of the CHMP, the EMA’s expert committee, a total of nine new drugs have been recommended while six drugs have had indication extensions accepted. Two treatments have been rejected.
Britt Meelby Jensen wants to rebuild trust in Ambu
After a turbulent time for Ambu under Juan Jose Gonzalez’s reign, new chief executive appointee Britt Meelby Jensen aims to rebuild the trust in the medtech firm, which has downgraded its expectations seven times over the past three years.
Outgoing Ambu CEO commends colleagues
”A true privilege,” says Juan Jose Gonzalez, describing his time as CEO at Ambu, which came to an end with Thursday’s announcement that Britt Meelby Jensen would take over the role.
Top news from MedWatch this week
Miss anything?
Clinical Trial Administrator 
IRT Manager, Clinical Drug Supply 
Scientific Writer 
SAP System Specialist (Product Supply) – Business Application Services 
KLIFO is looking for a Clinical Supply Manager for our Glostrup office 
Account Manager 
Communications Consultant 
Clinical Trial Manager 
Nordic Medical Affairs Manager 
System Sales Development Consultant - Investment Projects, Merck Millipore 
Director for innovative pre-clinical testing unit 
Analytical Senior Scientist 
Director Global Engineering 
Key Account Manager, Europe and Asia